SOX-9 as a prognostic marker in gastric adenocarcinoma

SRY-box transcription factor 9 (SOX9) has been reported to be overexpressed in a wide variety of gastrointestinal malignancies. While its role has been studied in gastric cancer (GC), the results remain conflicting. This study aimed to evaluate the relationship between SOX9 immunohistochemistry res...

Full description

Saved in:
Bibliographic Details
Main Authors: Efe Yetişgin, Aysun Gökçe, Kutsal Doğan
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2025-01-01
Series:Biomolecules & Biomedicine
Subjects:
Online Access:https://bjbms.org/ojs/index.php/bjbms/article/view/11928
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832542704140025856
author Efe Yetişgin
Aysun Gökçe
Kutsal Doğan
author_facet Efe Yetişgin
Aysun Gökçe
Kutsal Doğan
author_sort Efe Yetişgin
collection DOAJ
description SRY-box transcription factor 9 (SOX9) has been reported to be overexpressed in a wide variety of gastrointestinal malignancies. While its role has been studied in gastric cancer (GC), the results remain conflicting. This study aimed to evaluate the relationship between SOX9 immunohistochemistry results and the pathological and clinical characteristics of gastric adenocarcinoma, assessing its potential as a prognostic marker. Gastric tissue samples from 150 patients with gastric cancer were included in the study. Tissue sections were stained using an anti-SOX9 antibody, and relevant data were retrospectively collected from digital records. Immunostaining results were scored based on the proportion and intensity of stained nuclei throughout the tumor. A final immunostaining score was calculated by multiplying the SOX9 intensity score by the proportion score. Strong SOX9 nuclear staining was observed in 68 patients (45.3%), while moderate staining was seen in 60 patients (40%). SOX9 nuclear staining was absent in three patients (2%). A final SOX9 immunostaining score of ≥10, classified as high expression, was identified in 60 patients (40%). Patients with higher SOX9 expression or strong intensity scores exhibited significantly larger tumor sizes, higher rates of perineural and vascular invasion, more advanced T or lymph node staging, and greater likelihoods of lymphatic or distant metastases compared to those with lower SOX9 expression or intensity scores (all P < 0.05). These findings suggest that SOX9 staining intensity and expression are associated with increased tumor malignancy and disease progression. Therefore, SOX9 may serve as a prognostic pathological indicator in GC patients.
format Article
id doaj-art-22415ad525eb4f65b8a5acbc2c94c5c5
institution Kabale University
issn 2831-0896
2831-090X
language English
publishDate 2025-01-01
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format Article
series Biomolecules & Biomedicine
spelling doaj-art-22415ad525eb4f65b8a5acbc2c94c5c52025-02-03T16:42:09ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-01-0110.17305/bb.2024.11928SOX-9 as a prognostic marker in gastric adenocarcinomaEfe Yetişgin0https://orcid.org/0000-0002-0585-1125Aysun Gökçe1Kutsal Doğan2https://orcid.org/0000-0002-4208-6389Dışkapı Yıldırım Beyazıt Training and Research Hospital Department of Pathology, Ankara, TürkiyeDışkapı Yıldırım Beyazıt Training and Research Hospital Department of Pathology, Ankara, TürkiyeDışkapı Yıldırım Beyazıt Training and Research Hospital Department of Pathology, Ankara, Türkiye SRY-box transcription factor 9 (SOX9) has been reported to be overexpressed in a wide variety of gastrointestinal malignancies. While its role has been studied in gastric cancer (GC), the results remain conflicting. This study aimed to evaluate the relationship between SOX9 immunohistochemistry results and the pathological and clinical characteristics of gastric adenocarcinoma, assessing its potential as a prognostic marker. Gastric tissue samples from 150 patients with gastric cancer were included in the study. Tissue sections were stained using an anti-SOX9 antibody, and relevant data were retrospectively collected from digital records. Immunostaining results were scored based on the proportion and intensity of stained nuclei throughout the tumor. A final immunostaining score was calculated by multiplying the SOX9 intensity score by the proportion score. Strong SOX9 nuclear staining was observed in 68 patients (45.3%), while moderate staining was seen in 60 patients (40%). SOX9 nuclear staining was absent in three patients (2%). A final SOX9 immunostaining score of ≥10, classified as high expression, was identified in 60 patients (40%). Patients with higher SOX9 expression or strong intensity scores exhibited significantly larger tumor sizes, higher rates of perineural and vascular invasion, more advanced T or lymph node staging, and greater likelihoods of lymphatic or distant metastases compared to those with lower SOX9 expression or intensity scores (all P < 0.05). These findings suggest that SOX9 staining intensity and expression are associated with increased tumor malignancy and disease progression. Therefore, SOX9 may serve as a prognostic pathological indicator in GC patients. https://bjbms.org/ojs/index.php/bjbms/article/view/11928Gastric cancerGCSRY-box transcription factor 9SOX9adenocarcinomaprognosis
spellingShingle Efe Yetişgin
Aysun Gökçe
Kutsal Doğan
SOX-9 as a prognostic marker in gastric adenocarcinoma
Biomolecules & Biomedicine
Gastric cancer
GC
SRY-box transcription factor 9
SOX9
adenocarcinoma
prognosis
title SOX-9 as a prognostic marker in gastric adenocarcinoma
title_full SOX-9 as a prognostic marker in gastric adenocarcinoma
title_fullStr SOX-9 as a prognostic marker in gastric adenocarcinoma
title_full_unstemmed SOX-9 as a prognostic marker in gastric adenocarcinoma
title_short SOX-9 as a prognostic marker in gastric adenocarcinoma
title_sort sox 9 as a prognostic marker in gastric adenocarcinoma
topic Gastric cancer
GC
SRY-box transcription factor 9
SOX9
adenocarcinoma
prognosis
url https://bjbms.org/ojs/index.php/bjbms/article/view/11928
work_keys_str_mv AT efeyetisgin sox9asaprognosticmarkeringastricadenocarcinoma
AT aysungokce sox9asaprognosticmarkeringastricadenocarcinoma
AT kutsaldogan sox9asaprognosticmarkeringastricadenocarcinoma